Rahul Jandial, M.D., Ph.D.: Pediatric Neurosurgery Humanitarian Missions

March 13, 2018 | Denise Heady

Fourteen years ago, neurosurgeon and scientist Rahul Jandial, M.D., Ph.D., began to travel to underserved countries to perform brain surgeries on disadvantaged children.

Continue Reading

Custom Care: Personalized Treatment for Breast Cancer

July 21, 2017 | City of Hope

The term “personalized” gets used a lot in medicine these days. If you’ve received a breast cancer diagnosis, you’re probably wondering what personalized breast cancer care really means.

Targeted Therapy 101: A Primer

July 17, 2017 | City of Hope

Cancer care has come a long way. Surgery, chemotherapy and radiation have traditionally been the three pillars of cancer care, and they are still important treatments. But in recent years, newer “targeted therapies” have come on the scene.

Precision medicine isn't science fiction; access shouldn't be either

January 30, 2015 | Tami Dennis

If you haven’t heard the term “precision medicine,” you will. If you don’t have an opinion about access to it, you will. Precision medicine is expected to grow by leaps and bounds with the recently announced Precision Medicine Initiative.

Cancer research 2015: T cell immunotherapy, targeted drugs and more

January 1, 2015 | Tami Dennis

Every year, researchers make gains in the understanding of cancer, and physicians make gains in the treatment of cancer. As a result, every year, more cancer patients survive their disease. In 2015, cancer research will move forward in ways both high-profile and little-heralded.

Esophageal cancer 2015: Targeted therapy becomes an option

December 30, 2014 | Tami Dennis

City of Hope's Jae Kim offers his perspective on expected esophageal cancer advances for 2015. Think “precision.” Doctors can now prescribe specific drugs that focus specifically on cancer cells, avoiding the healthy cells that need to be preserved.

Unlocking Herceptin's potential against esophageal cancer

December 20, 2014 | Hiu Chung So

The protein HER2 is most commonly associated with breast cancer, but it also plays a role in several other cancers — including  esophageal cancer. Using this knowledge and the drug trastuzumab (Herceptin), which targets HER2, City of Hope researchers are conducting clinical trials with the hope of improving survival and quality of life for this hard-to-treat disease.

ASCO 2014: Two drug combo boosts ovarian cancer survival

May 31, 2014 | Hiu Chung So

For women with ovarian cancer, the results of recent study could mean new hope for future treatments. The findings, reported at the American Society of Clinical Oncology's annual meeting, found that a combination of two experimental drugs, olaparib and cediranib, significantly lengthened the duration of progression-free survival compared to olaparib alone and standard chemotherapy.

Meet our doctors: Hematologist Amrita Krishnan on multiple myeloma

February 7, 2014 | Kim Proescholdt

Multiple myeloma, a cancer of the blood plasma cells, is the second most common hematological malignancy in the U.S. (after non-Hodgkin lymphoma), and accounts for 1 percent of all cancers. It is generally thought to be incurable but highly treatable.

2 targeted drugs lack benefit for head, neck cancers, studies find

March 16, 2013 | Hiu Chung So

Targeted drugs are often touted as the holy grail of cancer therapy because they're able to hone in and kill cancer cells while leaving normal cells unscathed. Or that’s how they're supposed to work. Studies published earlier this month found that two targeted therapies did not benefit head and neck cancer patients, but the results provide direction for further research.